Voices of Meningitis, a public health initiative of the National Association of School Nurses (NASN) in collaboration with Sanofi Pasteur, announced today the launch of Get in the Game: Keeping Teens Healthy, a new program to help educate parents on the danger and prevention of meningococcal disease. Get in the Game will help raise awareness about the serious consequences of the disease and motivate parents to speak with their children's health care professional about vaccinating against meningococcal disease in advance of each sports season.
To view Multimedia News Release, go to http://www.multivu.com/players/English/61652-voices-of-meningitis-get-in-the-game/
Many parents had their children vaccinated when they were younger, but some vaccines are also recommended for older children. Beyond focusing on school supplies, extracurricular activities, and fall schedules, the back-to-school time is a good opportunity for parents to talk with their health care professional about vaccines that may be recommended for their preteen or teen.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62743-merck-webmd-healthywomen-back-to-school-means-back-to-vaccines
Building upon its efforts to provide greater access to vaccines and other health care services for populations in need, Walgreens (NYSE: WAG) (Nasdaq: WAG) is partnering with the United Nations Foundation this flu season, to help provide up to 3 million life-saving vaccines to children in developing countries through a donation to the Foundation’s Shot@Life campaign.
To view Multimedia News Release, go to http://www.multivu.com/players/English/62923-walgreens-flu-season2013
A new national survey shows most preteens and teens engage in day-to-day activities that may put them at risk of contracting meningococcal meningitis, a rare, but serious bacterial infection that can cause meningitis and take the life of an otherwise healthy child in just a single day. The National Association of School Nurses (NASN), in collaboration with Sanofi Pasteur, conducted the survey as part of its Voices of Meningitis back-to-school vaccination awareness initiative.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/voicesofmeningitis/50125/
Today the Confederation of Meningitis Organisations (CoMO) is urging people all over the world to “Join Hands Against Meningitis” in an effort to reduce the global impact of the disease. The call-to-action encourages individuals, families and communities to learn the signs and symptoms of meningitis, the importance of urgent treatment of the disease, and that prevention is available through vaccination against some forms of meningitis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55808-world-meningitis-day-join-the-fight-to-stop-meningitis
AstraZeneca announced today that it has collaborated with actor and father James Van Der Beek on a campaign to dispel common myths about the flu and underscore the importance of annual influenza vaccination for eligible individuals and families. As part of the campaign, Van Der Beek stars in an informative and comedic video, called “Just the Flu Facts,” in which he uses his signature sense of humor to debunk common misconceptions about seasonal influenza that are often barriers to vaccination.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7312451-medimmune-specialty-care-james-van-der-beek-flumist-quadrivalent-encourage-flu-shot/
Seqirus announced today that the National Adult and Influenza Immunization Summit (NAIIS) awarded the organization with the 2016 Immunization Excellence Award for best Corporate Campaign. The accolade recognizes Seqirus’ creative and collaborative efforts to improve vaccination awareness and rates during the 2015-16 influenza season. The award was presented yesterday during the NAIIS Summit in Atlanta, Georgia.
“We are pleased to receive this prestigious honor, and thankful to our partners, Families Fighting Flu and several collegiate student organizations, for their dedication to spreading the word about the dangers of flu and encouraging their peers to get vaccinated,” said Dr. Marie Mazur, Vice President of Global Commercial Development and Policy. “Moving forward, Seqirus is committed to building on this season’s success with college students and continuing the important work of flu prevention for all.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7833751-seqirus-national-award-knockoutflu/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
